BTG International Limited (2004) Use of triglyceride oils containing gamma-linolenic residues and linoleic acid residues for the treatment of neurodegenerative disease. WO2004/100943 A1.

Preview

PDF WO2004100943A1.pdf Download (1MB)

Abstract

A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a triglyceride oil containing both Ϝ-linolenic acid and linoleic acid residues as triglyceride ester, the ratio of Ϝ-linolenic acid to linoleic acid residues at the sn-2 position of the triglyceride being at least 0.8; the amount of Ϝ -linolenic acid residues at the sn-2 position being at least 18 %, wherein the oil is administered at a dose sufficient to maintain or elevate TGF- β1 levels in the patient at a therapeutic level. Preferably the method is that wherein the therapeutic level is such as to produce a TGF- βl/TNF-α ratio of at least 0.5 in blood of a patient, after 18 months of daily dosing. Preferre oils are Borage or Mucor oils having at least 35 % of the sn-2 position fatty acid residues as Ϝ-linolenic acid.

Item Type:	Patent
Additional Information:	Publication number WO2004100943 A1 Application number PCT/GB2004/002089
Uncontrolled Keywords:	Polyunsaturated fatty acids, treatment of multiple sclerosis
Subjects:	Q Science > QD Chemistry R Medicine > RM Therapeutics. Pharmacology
Faculty / School / Research Centre / Research Group:	Faculty of Education, Health & Human Sciences > School of Human Sciences (HUM)
Related URLs:	Organisation
Last Modified:	09 Oct 2021 04:46
URI:	http://gala.gre.ac.uk/id/eprint/4329

Actions (login required)

View Item

Downloads